Review highlights host-directed immunotherapies for challenging ocular fungal infections, addressing conventional treatment gaps
Background
Ocular fungal infections represent a significant global health burden, particularly prevalent in tropical and subtropical regions. Current antifungal therapies are often hampered by poor ocular bioavailability, delayed diagnosis, systemic toxicity, and limited efficacy, especially in immunocompromised individuals. This creates a critical gap in treatment, as host immunity plays a pivotal role in determining disease outcomes. Exploring immunomodulation as an adjunctive strategy aims to bolster the host's natural defenses while simultaneously reducing damaging immunopathology.
Study Design
This comprehensive review synthesized current literature on the complex interplay of innate and adaptive immune responses in ocular fungal infections. The authors explored emerging immunotherapeutic strategies, categorizing them into several key approaches: host defense peptides, cytokine therapies (e.g., IFN-γ, IL-6, IL-17, IL-33), cellular therapies (e.g., MSCs, CAR-T cells, dendritic cells), and extracellular vesicle-based interventions. The review analyzed their potential to enhance antifungal defense and mitigate immunopathology, contrasting these host-directed approaches with traditional pathogen-targeted treatments.
Results
The review identified several promising immunotherapeutic avenues for ocular fungal infections. Host defense peptides were highlighted for their direct antimicrobial properties and immunomodulatory effects. Cytokine therapies demonstrated potential to fine-tune immune responses; for instance, IFN-γ can bolster Th1 immunity, while IL-17 is crucial for antifungal defense at mucosal surfaces, and IL-33 can influence barrier function and type 2 immunity. > Cellular therapies, including Mesenchymal Stem Cells (MSCs) for their anti-inflammatory and regenerative properties, CAR-T cells for targeted fungal antigen recognition, and dendritic cells for enhancing adaptive immunity, were also explored. Furthermore, extracellular vesicle-based interventions emerged as a novel delivery system for immunomodulatory cargo, offering targeted action and reduced systemic side effects. These strategies collectively aim to enhance host antifungal defense and mitigate detrimental immunopathology.
Key Findings
- Conventional antifungal therapies for ocular fungal infections suffer from poor bioavailability, toxicity, and limited efficacy.
- Immunomodulation is an emerging adjunctive strategy to enhance antifungal defense and mitigate immunopathology.
- Host defense peptides offer direct antimicrobial action and immunomodulatory effects.
- Cytokine therapies (e.g.,
IFN-γ,IL-6,IL-17,IL-33) can fine-tune host immune responses. - Cellular therapies (
MSCs,CAR-T cells,dendritic cells) and extracellular vesicles show promise for targeted immunomodulation.
Why It Matters
This review signals a potential paradigm shift in treating ocular fungal infections, moving beyond solely pathogen-targeted drugs to more precise, host-directed interventions. For clinicians and researchers, this means exploring adjunctive therapies that leverage the body's own immune system, potentially improving outcomes where conventional antifungals fall short. The integration of immunomodulation could lead to more effective and less toxic treatment protocols, especially for immunocompromised patients. While still in early stages, the insights into host defense peptides, cytokine, cellular, and extracellular vesicle therapies lay the groundwork for future clinical trials, pushing towards a future where ocular fungal infections are managed with enhanced efficacy and reduced immunopathology.
ocular fungal infections
immunotherapy
host defense peptides
cytokine therapy
cellular therapy
extracellular vesicles